Objective: This study aimed to systematically review the efficacy and safety of Guanxin Danshen drop pill for coronary heart disease (CHD). Method: We search the literatures on randomized controlled trials (RCTs) using Guanxin Danshen drop pill for the treatment of coronary heart disease from public database such as Pubmed

Cochrane library

China Biology Medicine disc(CBM)

CNKI

and Wanfang Data. RevMan5.2 was used in the analysis. Result: Fifty RCTs including 1 455 patients met the inclusion criteria. All the trials were not adequate in methodological quality. None of them was double-blinded trial. There was a significant funnel plot asymmetry

which means publication bias has been found. Compared with the control group

the treatment group showed significantly higher total effective rate at improving angina symptoms

and the total effectiveness rate at ameliorating the electrocardiogram effect

as well.As for the indexes of blood rheology

blood viscosity

plasma viscosity

hematocrit and fibrinogen in treatment group were superior to the contrast group(P<0.01)

weighted mean difference were [-0.86

95%CI(-1.43

-0.28)]

[-0.35

95%CI(-0.56

-0.15)]

[-3.3

95%CI(-4.07

-2.53)]

[-0.76

95%CI(-1.05

-0.48)]. There were no obvious side-effects found in the trials. [WTHZ]Conclusion:[WTBZ]The present Meta-analysis suggested that on the basis of conventional western medicine

Guanxin Danshen drop pill is helpful to improve symptoms

alleviate the ischemia of electrocardiogram and improve blood rheology indexes

however

high-quality evidences of evidence-based medicine(EBM) are needed due to publication bias and low quality of RCT.